Product Images Gemfibrozil
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Gemfibrozil NDC 50090-7809 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Additional Adverse Reactions - Additional Adv Drug Reactions
This text provides information on potential adverse effects and side effects of a medication. It lists various symptoms and conditions related to the central nervous system, gastrointestinal system, genitourinary system, musculoskeletal system, clinical laboratory findings, hematopoietic system, immunologic system, and integumentary system. Some examples of the listed effects include weight loss, cardiac issues, gastrointestinal problems, CNS issues like dizziness and confusion, musculoskeletal pain, laboratory abnormalities, immunologic reactions, and skin conditions. The medication appears to have a wide range of potential side effects and interactions that should be considered.*
Adverse Reactions - Adv Reactions
Struct - Structure Gemfibrozil
Table1 - Table 1
Table showing the reduction in Coronary Heart Disease (CHD) rates per 1000 patients based on baseline lipid levels in the Helsinki Heart Study. The data includes the number of events over a period of 0-5 years for all patients and specific lipid categories such as LDL-C, HDL-C, and TG. Comparisons between placebo and Gemfibrozil groups are provided for different lipid levels in mg/dL. The table lists the occurrence of fatal and nonfatal events like myocardial infarctions and sudden cardiac deaths.*
Table2 - Table 2
This text provides a table showing the number of cardiac events and all-cause mortality per 1000 patients that occurred during a 3.5-year open-label follow-up to the Helsinki Heart Study. The groups are categorized based on the original randomization (P = placebo, G = Gemfibrozil) and by the drug taken during the follow-up period (N = Attend clinic but took no drug, G = Gemfibrozil, Drop = No attendance at clinic during open-label). The data includes patient numbers and event rates for cardiac events and all-cause mortality in each group.*
Table3 - Table 3
This text provides a detailed comparison of cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality in the Helsinki Heart Study over a span of 8.5 years, specifically analyzing the impact of gemfibrozil versus a placebo. The analysis includes hazard ratios and confidence intervals for various events such as cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality. The study uses an intention-to-treat analysis and focuses on originally randomized patients while disregarding open-label treatment switches and exposure to study conditions. The data presented relates to fatal and non-fatal myocardial infarctions along with sudden cardiac deaths over the 8.5-year duration.*
Label Image - lbl500907809
This is a product description for Gemfibrozil USP 600mg tablets with a product number of 53695-0. Each bottle contains 90 tablets and is available for purchase. The tablets are stored in a secure container.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
